Covid survivors are twice as likely to have side effects from the Pfizer vaccine

by

Covid survivors are nearly twice as likely to suffer side effects from the Pfizer vaccine compared to those who never contracted the virus, according to the data.

Figures from a symptom tracking app show that 33% of people who had already suffered from the virus suffered at least one mild side effect, such as fatigue or headache within a week of receiving the sting.

By comparison, the rate was 19% among noncovid patients.

The ZOE Covid-19 Symptom Study application revealed that the most common side effect was fatigue, with nine percent. He was followed by headaches (eight percent) and chills (four percent).

Meanwhile, the data also show most of the side effects, known as systemic because the whole body is affected, that appear within 48 hours after vaccination.

Only three percent experienced complications that lasted more than three days.

The ZOE Covid-19 Symptom Study application revealed that 33% of those who had previously contracted the virus experienced one or more mild side effects after seven days, compared with 19% of patients who were not covid.

The ZOE Covid-19 Symptom Study application revealed that 33% of those who had previously contracted the virus experienced one or more mild side effects after seven days, compared with 19% of those who did not have covid.

Covid survivors are nearly twice as likely to suffer side effects from the Pfizer vaccine compared to those who never contracted the virus, according to the data.

Covid survivors are nearly twice as likely to suffer side effects from the Pfizer vaccine compared to those who never contracted the virus, according to the data.

Professor Tim Spector, an epidemiologist at King’s College London, who runs the ZOE Symptom app, which also calculates infections nationwide, said the data suggests the first dose for those who have previously had Covid is behaves like a reinforcing spike.

The study analyzed data from people of all ages who had 40,000 doses between them.

37% were found to have pain or swelling near the puncture site after the first dose, which increased to 45% after the second dose.

The data also showed that 14% of participants reported at least one side effect within seven days of the first dose, compared with 22% after the second injection: suggesting a relapse dose elicits an immune response. stronger.

Figures show that 13% of men had at least one side effect in seven days, compared with 19% of women who had received the vaccine.

Children under 55 were more likely to experience a side effect, with 21% registering at least one symptom compared with 14% over 55 years.

Commenting on the effects after the Pfizer / BioNTech vaccination, he said: “It really suggests that if you had Covid before the first vaccine, it behaves a bit like the second, as a booster.

He described how the highest rate of side effects seen in people who had previously had Covid suggests that: “People already had an immune response and get even greater boost to make their immunity stronger.”

Professor Spector added: “I hope that once we analyze and get a little more of the data we will show that this group that previously had Covid, maybe six months earlier, has even greater protection, even over 53% after this single dose.

To date, the UK has placed orders for 367 million doses of the seven most promising Covid vaccines, made by AstraZeneca, Pfizer, Moderna, Valneva, Janssen, GlaxoSmithKline and Novavax, at a cost of £ 2.9 million

To date, the UK has placed orders for 367 million doses of the seven most promising Covid vaccines, made by AstraZeneca, Pfizer, Moderna, Valneva, Janssen, GlaxoSmithKline and Novavax, at a cost of £ 2.9 million

Pfizer / BioNTech's innovative breakthrough was the first in the world to be shown to successfully block the severe Covid-19 last year and gain approval in the UK on 2 December

Pfizer / BioNTech’s innovative breakthrough was the first in the world to be shown to successfully block severe Covid-19 last year and gain approval in the UK on 2 December

Covid survivors may only need one dose of vaccine because they already have antibodies

A new study suggests that people previously infected with coronavirus only need one dose of the vaccine.

The researchers found that participants who had contracted COVID-19 in the past and had been shot had levels of antibodies similar – and even higher – than those who had never been infected and were given two. dose.

In addition, virus survivors were more likely to report side effects after being immunized, such as pain at the injection site, fever, and fatigue.

The team, from the Icahn School of Medicine in Mount Sinai, New York, says administering the previously infected individuals just one dose “would save them unnecessary pain and release many doses of vaccine they urgently needed.”

“I think it invites the question of whether with a little more data we could say that these people do not need a second reinforcement and that they have really already had the first which is the Covid and the second which is the first vaccination.

“That could save about 10 million vaccines, or at least it could be delayed maybe a few more months.”

The first time in the world it was shown that it successfully blocked the severe Covid-19 last year and gained approval in the UK on 2 December.

It uses a new technology and is known as the messenger RNA (mRNA) vaccine. Conventional vaccines are produced by weakened forms of the virus, but mRNAs only use the genetic code of the virus.

An mRNA vaccine is injected into the body where it enters the cells and tells them to create antigens. These antigens are recognized by the immune system and prepare it to fight the coronavirus.

Studies showed that the two-dose vaccine could prevent serious illness in 95% of people who were injected.

The government has ordered 40 million doses, enough to vaccinate 20 million Britons, but only a handful of millions of Britons have received the puncture so far.

Having vaccines to order is not the same as having them ready to start. Manufacturers are still trying to increase production to supply agreed supplies worldwide.

The UK ran into some logistical difficulties when it tried to launch the vaccine last year, which halted the speed with which it could be deployed.

The disadvantage of mRNA vaccines is that they need to be stored at ultra-cold temperatures and cannot be easily transported.

HOW DO THE UK-APPROVED MODERN, OXFORD AND PFIZER VACCINES COMPARE?

Moderna and Pfizer / BioNTech have published provisional results of clinical trials of the final phase of their vaccines, both of which suggest that they are extremely effective.

Oxford University has published the results of its second phase, which show that the puncture elicits an immune response and is safe to use; it is not yet clear to what extent it protects against coronavirus in the real world.

Here’s how they compare:

PFIZER (USA) and BIONTECH (DE)

MRNA Vaccine: The genetic material of the coronavirus is injected to trick the immune system into making “spike” proteins and learn how to attack them.

MRNA Vaccine: Moderna and Pfizer and BioNTech vaccines work the same way.

Recombinant viral virus vaccine: A harmless cold virus extracted from chimpanzees was released to produce “spike” proteins and look like coronavirus.

94.5% effective (90 positives in the placebo group, 5 positives in the vaccine group).

95% effective (160 positives in the placebo group, 8 positives in the vaccine group).

62% – 90% effective, depending on the dosage.

Moderna confirmed that it will charge countries that place smaller orders, such as the UK’s five million doses, between £ 24 and £ 28 per dose. The United States has secured doses of $ 100 million for $ 1.525 billion (£ 1.16 billion), suggesting it will cost $ 15.25 (£ 11.57) per dose.

The United States will pay $ 1.95 billion (£ 1.48 billion) for the first 100 million doses, a cost of $ 19.50 (£ 14.80) per dose.

It is expected to cost £ 2.23 per dose. The full 100 million dose supply from the UK could amount to just £ 223 million.

The UK has ordered five million doses that will be available from March 2021. Modern will produce doses of 20 million this year, which are expected to remain in the US.

The UK has already ordered 40 million doses, of which 10 million could be available by 2020. The first vaccines are expected in December.

The UK has already ordered 100 million doses and is expected to be the first to achieve this once approved.

What side effects does it cause?

Modern said the vaccine is “generally safe and well tolerated.” Most side effects were mild or moderate, but included pain, fatigue, and headaches, which were “usually” short-lived.

Pfizer and BioNTech did not produce a breakdown of side effects, but said the Data Monitoring Committee “has not reported any serious security issues.”

Oxford said there were no serious security concerns. Mild side effects have been relatively common in small trials, and many participants reported that it hurt their arm after the puncture and they subsequently suffered from headaches, exhaustion, or muscle aches. More data is being collected.

.Source